Glenmark launches Teneligliptin + Pioglitazone Fixed-Dose Combination drug for type-II diabetes in India

Glenmark Pharma has launched a novel Fixed-Dose Combination (FDC) of a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone. This is the only available DPP4 and Glitazone combination brand in India for adults with uncontrolled type-II diabetes, Glenmark informed in a statement.

The company has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) + Pioglitazone (15 mg), to be taken once a day, the statement added.

It also notified that Glenmark is the first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the Drug Controller General of India (DCGI).  This Fixed-Dose Combination will be useful for patients who require treatment with Teneliglitptin and Pioglitazone (as separate drugs) to improve glycemic control reducing insulin resistance.

Type-II diabetics typically face issues of β cell dysfunction and insulin resistance. Glenmark’s FDC of Teneligliptin
+ Pioglitazone has the efficacy to tackle these two most important pathophysiologies which make the FDC more effective in managing uncontrolled type-II diabetes. The combination of Teneligliptin + Pioglitazone will provide a synergistic approach wherein Teneligliptin will optimally improve β cell sensitivity, and Pioglitazone will effectively reduce insulin resistance, concluded the statement.